Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D08LFZ
|
||||
Former ID |
DAP000152
|
||||
Drug Name |
Diflunisal
|
||||
Synonyms |
Adomal; Algobid; Citidol; Difludol; Diflunisalum; Dolisal; Dolobid; Dolobil; Dolobis; Dolocid; Flovacil; Fluniget; Fluodonil; Flustar; Noaldol; Reuflos; Unisal; Apotex Brand of Diflunisal; Cahill May Roberts Brand of Diflunisal; Diflunisal Novopharm Brand; Frosst SA Brand of Diflunisal; Merck Brand of Diflunisal; Novopharm Brand of Diflunisal; Nu Pharm Brand of Diflunisal; MK 647; MK647; Apo-Diflunisal; Diflunisalum [INN-Latin]; Dolobid (TN); MK-647; Merck Sharp & Dohme Brand of Diflunisal; Novo-Diflunisal; Nu-Diflunisal; Nu-Pharm Brand of Diflunisal; Diflunisal (JAN/USP/INN); Diflunisal [USAN:INN:BAN:JAN]; 2',4'-Difluoro-4-hydroxy-(1,1'-biphenyl)-3-carboxylic acid; 2',4'-Difluoro-4-hydroxy-3-biphenylcarboxylic acid; 2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid; 2-(Hydroxy)-5-(2,4-difluorophenyl)benzoic acid; 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID; 5-(2,4-Difluorophenyl)salicylic acid; 5-(2,4-difluorophenyl)-2-hydroxybenzoic acid; 5-[2,4-Difluorophenyl]salicylic acid
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Analgesics
|
||||
Company |
Merck & Co
|
||||
Structure |
Download2D MOL |
||||
Formula |
C13H8F2O3
|
||||
InChI |
InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)
|
||||
InChIKey |
HUPFGZXOMWLGNK-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 22494-42-4
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
4832, 855794, 3220269, 5635336, 7847198, 7885083, 7979080, 8027938, 8149302, 8151945, 10321268, 10514228, 11112675, 11336113, 11361352, 11363856, 11366418, 11368980, 11371523, 11374224, 11377142, 11462324, 11466067, 11467187, 11484899, 11485794, 11488828, 11490208, 11492328, 11494776, 12013398, 15221177, 24893742, 26611703, 26679788, 26697369, 26746997, 26746998, 29222205, 46507807, 47216844, 47365272, 47440348, 47589066, 47736568, 47810827, 47959840, 48415892, 49698694, 49738138
|
||||
ChEBI ID |
ChEBI:39669
|
||||
SuperDrug ATC ID |
N02BA11
|
||||
SuperDrug CAS ID |
cas=022494424
|
||||
Target and Pathway | |||||
Target(s) | Prostaglandin G/H synthase 2 | Target Info | Inhibitor | [535160] | |
KEGG Pathway | Arachidonic acid metabolism | ||||
Metabolic pathways | |||||
NF-kappa B signaling pathway | |||||
VEGF signaling pathway | |||||
TNF signaling pathway | |||||
Retrograde endocannabinoid signaling | |||||
Serotonergic synapse | |||||
Ovarian steroidogenesis | |||||
Oxytocin signaling pathway | |||||
Regulation of lipolysis in adipocytes | |||||
Leishmaniasis | |||||
Pathways in cancer | |||||
Chemical carcinogenesis | |||||
MicroRNAs in cancer | |||||
Small cell lung cancer | |||||
PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
References | |||||
Ref 538256 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 073562. | ||||
Ref 542171 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7162). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.